Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17,760 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of HLX01 in patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a phase 3 study.
Zeng X, Liu J, Liu X, Wu L, Liu Y, Liao X, Liu H, Hu J, Lu X, Chen L, Xu J, Jiang Z, Lu FA, Wu H, Li Y, Wang Q, Zhu J; HLX01-RA03 Investigators. Zeng X, et al. Among authors: jiang z. Arthritis Res Ther. 2022 Jun 10;24(1):136. doi: 10.1186/s13075-022-02821-x. Arthritis Res Ther. 2022. PMID: 35689239 Free PMC article. Clinical Trial.
Chinese Registry of rheumatoid arthritis (CREDIT): II. prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis.
Jin S, Li M, Fang Y, Li Q, Liu J, Duan X, Liu Y, Wu R, Shi X, Wang Y, Jiang Z, Wang Y, Yu C, Wang Q, Tian X, Zhao Y, Zeng X; CREDIT Co-authors. Jin S, et al. Among authors: jiang z. Arthritis Res Ther. 2017 Nov 15;19(1):251. doi: 10.1186/s13075-017-1457-z. Arthritis Res Ther. 2017. PMID: 29141688 Free PMC article.
Chinese registry of rheumatoid arthritis (CREDIT): I. Introduction and prevalence of remission in Chinese patients with rheumatoid arthritis.
Yu C, Li M, Duan X, Fang Y, Li Q, Wu R, Liu S, Wang Y, Wu Z, Shi X, Jiang Z, Wang Y, Hsieh ED, Jin S, Jiang N, Wang Q, Zhao Y, Tian X, Zeng X; and the co-authors of CREDIT. Yu C, et al. Among authors: jiang n, jiang z. Clin Exp Rheumatol. 2018 Sep-Oct;36(5):836-840. Epub 2018 Mar 21. Clin Exp Rheumatol. 2018. PMID: 29600939 Free article.
Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study.
Bi L, Li Y, He L, Xu H, Jiang Z, Wang Y, Li X, Wei W, Gu J, Wang G, Zhang Z, Zhou B, Liu Y, Wu Z, Liu H, He D, Lv Z, Li Z, Zuo X, Dong L, Wu H, Zhang H, Chen H, Bao C, Zhang Z, Zhang M, Song H, Zheng Y, Jiang L, Liu X, Boehnlein M, Dunkel J, Shao J, Harris K, Li Z. Bi L, et al. Among authors: jiang l, jiang z. Clin Exp Rheumatol. 2019 Mar-Apr;37(2):227-234. Epub 2018 Aug 29. Clin Exp Rheumatol. 2019. PMID: 30183595 Free article. Clinical Trial.
Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II study.
Lin Y, Chen X, Ding H, Ye P, Gu J, Wang X, Jiang Z, Li D, Wang Z, Long W, Li Z, Jiang G, Li X, Bi L, Jiang L, Wu J, Guo L, Cai X, Lu X, Chen Q, Chen H, Peng A, Zuo X, Ning R, Zhang Z, Tai Y, Zhang T, Bao C. Lin Y, et al. Among authors: jiang g, jiang l, jiang z. Rheumatology (Oxford). 2021 Nov 3;60(11):5089-5097. doi: 10.1093/rheumatology/keab198. Rheumatology (Oxford). 2021. PMID: 33693494 Clinical Trial.
Fine Comparison of the Efficacy and Safety Between GB242 and Infliximab in Patients with Rheumatoid Arthritis: A Phase III Study.
Liu Y, Liu S, Liu L, Gong X, Liu J, Sun L, Liu X, Wu L, Chen L, Wang L, Luo L, Lin J, Tie N, Jiang Z, Wu J, Lu F, Sun H, Li X, Yang N, Chai K, Wei H, Da Z, Zhao C, Dai L, Wang Y, Shi G, Zhang Z, Song H, Guo Q, Liu YC, Li Z. Liu Y, et al. Among authors: jiang z. Rheumatol Ther. 2022 Feb;9(1):175-189. doi: 10.1007/s40744-021-00396-8. Epub 2021 Nov 22. Rheumatol Ther. 2022. PMID: 34806155 Free PMC article.
17,760 results
You have reached the last available page of results. Please see the User Guide for more information.